메뉴 건너뛰기




Volumn 238, Issue 8, 2011, Pages 1004-1010

Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

EID: 79955617143     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.238.8.1004     Document Type: Article
Times cited : (40)

References (43)
  • 1
    • 65349104376 scopus 로고    scopus 로고
    • Tumors of the urinary system
    • In: Withrow SJ, Vail DM, eds., 4th ed. Philadelphia: WB Saunders Co
    • Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM, eds. Withrow & MacEwen's small animal clinical oncology. 4th ed. Philadelphia: WB Saunders Co, 2007;649-658.
    • (2007) Withrow & MacEwen's small animal clinical oncology , pp. 649-658
    • Knapp, D.W.1
  • 3
    • 0038079730 scopus 로고    scopus 로고
    • Management of transitional cell carcinoma
    • Henry CJ. Management of transitional cell carcinoma. Vet Clin North Am Small Anim Pract 2003;33:597-613.
    • (2003) Vet Clin North Am Small Anim Pract , vol.33 , pp. 597-613
    • Henry, C.J.1
  • 4
    • 0028477323 scopus 로고
    • Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder
    • Knapp D, Richardson R, Chan T, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
    • (1994) J Vet Intern Med , vol.8 , pp. 273-278
    • Knapp, D.1    Richardson, R.2    Chan, T.3
  • 5
    • 0025428107 scopus 로고
    • Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra: A retrospective study of 15 dogs
    • Moore AS, Cardona A, Shapiro W, et al. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra: a retrospective study of 15 dogs. J Vet Intern Med 1990;4:148-152.
    • (1990) J Vet Intern Med , vol.4 , pp. 148-152
    • Moore, A.S.1    Cardona, A.2    Shapiro, W.3
  • 6
    • 0029818273 scopus 로고    scopus 로고
    • Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993)
    • Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc 1996;209:1588-1591.
    • (1996) J Am Vet Med Assoc , vol.209 , pp. 1588-1591
    • Chun, R.1    Knapp, D.W.2    Widmer, W.R.3
  • 7
    • 0033806440 scopus 로고    scopus 로고
    • Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer
    • Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221-226.
    • (2000) Cancer Chemother Pharmacol , vol.46 , pp. 221-226
    • Knapp, D.W.1    Glickman, N.W.2    Widmer, W.R.3
  • 8
    • 35548986259 scopus 로고    scopus 로고
    • Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder
    • Greene SN, Lucroy MD, Greenberg CB, et al. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2007;231:1056-1060.
    • (2007) J Am Vet Med Assoc , vol.231 , pp. 1056-1060
    • Greene, S.N.1    Lucroy, M.D.2    Greenberg, C.B.3
  • 9
    • 0031217671 scopus 로고    scopus 로고
    • Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder
    • Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
    • (1997) J Vet Intern Med , vol.11 , pp. 279-283
    • Chun, R.1    Knapp, D.W.2    Widmer, W.R.3
  • 10
    • 33746404198 scopus 로고    scopus 로고
    • Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder
    • Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
    • (2005) Vet Comp Oncol , vol.3 , pp. 73-80
    • Boria, P.A.1    Glickman, N.W.2    Schmidt, B.R.3
  • 11
    • 0025764952 scopus 로고
    • Efficacy of mitoxantrone against various neoplasms in dogs
    • Ogilvie GK, Obradovich JE, Elmslie RE, et al. Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc 1991;198:1618-1621.
    • (1991) J Am Vet Med Assoc , vol.198 , pp. 1618-1621
    • Ogilvie, G.K.1    Obradovich, J.E.2    Elmslie, R.E.3
  • 12
    • 0037314711 scopus 로고    scopus 로고
    • Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma
    • Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
    • (2003) Clin Cancer Res , vol.9 , pp. 906-911
    • Henry, C.J.1    McCaw, D.L.2    Turnquist, S.E.3
  • 13
    • 0034277451 scopus 로고    scopus 로고
    • Prognostic factors in dogs with urinary bladder carcinoma
    • Rocha TA, Mauldin GN, Patnaik AK, et al. Prognostic factors in dogs with urinary bladder carcinoma. J Vet Intern Med 2000;14:486-490.
    • (2000) J Vet Intern Med , vol.14 , pp. 486-490
    • Rocha, T.A.1    Mauldin, G.N.2    Patnaik, A.K.3
  • 14
    • 0028221316 scopus 로고
    • Comparison of three treatments for transitional cell carcinoma of the bladder in the dog
    • Helfand SC, Hamilton TA, Hungerford LL, et al. Comparison of three treatments for transitional cell carcinoma of the bladder in the dog. J Am Anim Hosp Assoc 1994;30:270-275.
    • (1994) J Am Anim Hosp Assoc , vol.30 , pp. 270-275
    • Helfand, S.C.1    Hamilton, T.A.2    Hungerford, L.L.3
  • 15
    • 0036125840 scopus 로고    scopus 로고
    • Future directions for gemcitabine in the treatment of genitourinary cancer
    • Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin Oncol 2002;29:40-45.
    • (2002) Semin Oncol , vol.29 , pp. 40-45
    • Vogelzang, N.J.1
  • 16
    • 0036077791 scopus 로고    scopus 로고
    • Overview: Gemcitabine as single-agent therapy for advanced breast cancer
    • Tripathy D. Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer 2002;3:8-11.
    • (2002) Clin Breast Cancer , vol.3 , pp. 8-11
    • Tripathy, D.1
  • 17
    • 0034158324 scopus 로고    scopus 로고
    • Gemcitabine in the treatment of bladder cancer
    • Ryan CW, Vogelzang NJ. Gemcitabine in the treatment of bladder cancer. Expert Opin Pharmacother 2000;1:547-553.
    • (2000) Expert Opin Pharmacother , vol.1 , pp. 547-553
    • Ryan, C.W.1    Vogelzang, N.J.2
  • 18
    • 0035082324 scopus 로고    scopus 로고
    • Phase I trial of gemictabine in patients with advanced pancreatic cancer
    • Okada S, Ueno H, Okusaka T, et al. Phase I trial of gemictabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
    • (2001) Jpn J Clin Oncol , vol.31 , pp. 7-12
    • Okada, S.1    Ueno, H.2    Okusaka, T.3
  • 19
    • 2942571455 scopus 로고    scopus 로고
    • Gemcitabine (Gemzar) in non-small cell lung cancer
    • Manegold C. Gemcitabine (Gemzar) in non-small cell lung cancer. Expert Rev Anticancer Ther 2004;4:345-360.
    • (2004) Expert Rev Anticancer Ther , vol.4 , pp. 345-360
    • Manegold, C.1
  • 20
    • 0036182570 scopus 로고    scopus 로고
    • The role of gemcitabine in the treatment of malignant mesothelioma
    • Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 2002;29:70-76.
    • (2002) Semin Oncol , vol.29 , pp. 70-76
    • Kindler, H.L.1    van Meerbeeck, J.P.2
  • 21
    • 0035424877 scopus 로고    scopus 로고
    • Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation
    • Patel SRR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489.
    • (2001) J Clin Oncol , vol.19 , pp. 3483-3489
    • Patel, S.R.R.1    Gandhi, V.2    Jenkins, J.3
  • 22
    • 0141731181 scopus 로고    scopus 로고
    • Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma
    • Jones PD, de Lorimier LP, Kitchell BE, et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 2003;39:463-467.
    • (2003) J Am Anim Hosp Assoc , vol.39 , pp. 463-467
    • Jones, P.D.1    de Lorimier, L.P.2    Kitchell, B.E.3
  • 23
    • 7244221409 scopus 로고    scopus 로고
    • Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study
    • LeBlanc AK, LaDue TA, Turrel JM, et al. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004;45:466-470.
    • (2004) Vet Radiol Ultrasound , vol.45 , pp. 466-470
    • LeBlanc, A.K.1    LaDue, T.A.2    Turrel, J.M.3
  • 24
    • 13544269471 scopus 로고    scopus 로고
    • Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies
    • Kosarek CE, Kisseberth WC, Gallant SL, et al. Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 2005;19:81-86.
    • (2005) J Vet Intern Med , vol.19 , pp. 81-86
    • Kosarek, C.E.1    Kisseberth, W.C.2    Gallant, S.L.3
  • 25
    • 61749098352 scopus 로고    scopus 로고
    • Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs
    • Marconato L, Lorenzo MR, Abramo F, et al. Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 2008;6:90-101.
    • (2008) Vet Comp Oncol , vol.6 , pp. 90-101
    • Marconato, L.1    Lorenzo, M.R.2    Abramo, F.3
  • 26
    • 0038186551 scopus 로고    scopus 로고
    • Antimetabolites
    • In: Perry MC, ed., Philadelphia: Lippincott Williams & Wilkins
    • Gutheil JC, Finucane DM. Antimetabolites. In: Perry MC, ed. The chemotherapy source book. Philadelphia: Lippincott Williams & Wilkins, 2001;219-220.
    • (2001) The chemotherapy source book , pp. 219-220
    • Gutheil, J.C.1    Finucane, D.M.2
  • 27
    • 0025978216 scopus 로고
    • A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
    • Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
    • (1991) J Clin Oncol , vol.9 , pp. 491-498
    • Abbruzzese, J.L.1    Grunewald, R.2    Weeks, E.A.3
  • 28
    • 0029852961 scopus 로고    scopus 로고
    • Phase I studies with the novel nucleoside analog gemcitabine
    • Abbruzzese JL. Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol 1996;23:25-31.
    • (1996) Semin Oncol , vol.23 , pp. 25-31
    • Abbruzzese, J.L.1
  • 29
    • 0029973099 scopus 로고    scopus 로고
    • Gemcitabine: Once-weekly schedule active and better tolerated than twice-weekly schedule
    • Martin C, Lund B, Anderson H, et al. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 1996;7:351-357.
    • (1996) Anticancer Drugs , vol.7 , pp. 351-357
    • Martin, C.1    Lund, B.2    Anderson, H.3
  • 30
    • 0029666336 scopus 로고    scopus 로고
    • Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors
    • Veerman G, Ruiz van Haperen VW, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-342.
    • (1996) Cancer Chemother Pharmacol , vol.38 , pp. 335-342
    • Veerman, G.1    van Haperen Ruiz, V.W.2    Vermorken, J.B.3
  • 31
    • 0032834698 scopus 로고    scopus 로고
    • Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs
    • Cozzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999;5:2629-2637.
    • (1999) Clin Cancer Res , vol.5 , pp. 2629-2637
    • Cozzi, P.J.1    Bajorin, D.F.2    Tong, W.3
  • 34
    • 0031090416 scopus 로고    scopus 로고
    • Sonographic evaluation of urinary bladder wall thickness in normal dogs
    • Geisse AL, Lowry JE, Schaeffer DJ, et al. Sonographic evaluation of urinary bladder wall thickness in normal dogs. Vet Radiol Ultrasound 1997;38:132-137.
    • (1997) Vet Radiol Ultrasound , vol.38 , pp. 132-137
    • Geisse, A.L.1    Lowry, J.E.2    Schaeffer, D.J.3
  • 35
    • 26844522727 scopus 로고    scopus 로고
    • Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0
    • Veterinary Cooperative Oncology Group
    • Veterinary Cooperative Oncology Group. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
    • (2004) Vet Comp Oncol , vol.2 , pp. 194-213
  • 36
    • 0030686593 scopus 로고    scopus 로고
    • Gemcitabine: A promising new agent in the treatment of urothelial cancer
    • Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of urothelial cancer. J Clin Onc 1997;15:3441-3445.
    • (1997) J Clin Onc , vol.15 , pp. 3441-3445
    • Moore, M.J.1    Tannock, I.F.2    Ernst, D.S.3
  • 37
    • 0019487795 scopus 로고
    • Bladder cancer in pet dogs: A sentinel for environmental cancer?
    • Hayes HM Jr, Hoover R, Tarone RE. Bladder cancer in pet dogs: a sentinel for environmental cancer? Am J Epidemiol 1981;114:229-233.
    • (1981) Am J Epidemiol , vol.114 , pp. 229-233
    • Hayes Jr., H.M.1    Hoover, R.2    Tarone, R.E.3
  • 38
    • 17544402702 scopus 로고    scopus 로고
    • Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer
    • Mohammed SI, Craig BA, Mutsaers AJ, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003;2:183-188.
    • (2003) Mol Cancer Ther , vol.2 , pp. 183-188
    • Mohammed, S.I.1    Craig, B.A.2    Mutsaers, A.J.3
  • 39
    • 0033990160 scopus 로고    scopus 로고
    • Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer
    • Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:47-49.
    • (2000) Urol Oncol , vol.5 , pp. 47-49
    • Knapp, D.W.1    Glickman, N.W.2    DeNicola, D.B.3
  • 40
    • 42249087303 scopus 로고    scopus 로고
    • Prediction of broad spectrum resistance of tumors towards anticancer drugs
    • Efferth T, Konkimalla VB, Wang YF, et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 2008;14:2405-2412.
    • (2008) Clin Cancer Res , vol.14 , pp. 2405-2412
    • Efferth, T.1    Konkimalla, V.B.2    Wang, Y.F.3
  • 41
    • 0141520276 scopus 로고    scopus 로고
    • Drug resistance and the microenvironment: Nature and nurture
    • Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003;6:169-172.
    • (2003) Drug Resist Updat , vol.6 , pp. 169-172
    • Morin, P.J.1
  • 42
    • 0028889426 scopus 로고
    • Scheduledependent antitumor effect of gemcitabine in in vivo model system
    • Braakhuis BJ, Ruiz van Haperen VW, Boven E, et al. Scheduledependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995;22:42-46.
    • (1995) Semin Oncol , vol.22 , pp. 42-46
    • Braakhuis, B.J.1    van Haperen Ruiz, V.W.2    Boven, E.3
  • 43
    • 0027263596 scopus 로고
    • The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
    • Boven E, Schipper H, Erkelens CA, et al. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993;68:52-56.
    • (1993) Br J Cancer , vol.68 , pp. 52-56
    • Boven, E.1    Schipper, H.2    Erkelens, C.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.